A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants. by Pace, D, Snape, M, Westcar, S, Hamaluba, M, Yu, L, Begg, N, Wysocki, J, Czajka, H, Maechler, G, Boutriau, D, Pollard, A

“…We conducted a phase 3 randomized controlled trial looking at the immunogenicity and safety of a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine, Hib-MenC-TT in a 2-, 3-, and 4-month primary infant immunization schedule. …”

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine by De Whalley, P, Snape, MD, Kelly, D, Banner, C, Lewis, S, Diggle, L, John, T, Yu, L, Omar, O, Borkowski, A, Pollard, A

“…Background: Bactericidal antibody induced by immunization of infants with serogroup C Neisseria meningitidis (MenC) vaccines wanes rapidly during childhood. …”

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine. by de Whalley, P, Snape, MD, Kelly, D, Banner, C, Lewis, S, Diggle, L, John, T, Yu, L, Omar, O, Borkowski, A, Pollard, A

“… BACKGROUND: Bactericidal antibody induced by immunization of infants with serogroup C Neisseria meningitidis (MenC) vaccines wanes rapidly during childhood. …”

Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster... by Snape, MD, Philip, J, John, T, Robinson, H, Kelly, S, Gossger, N, Yu, L, Kittel, C, Toneatto, D, Dull, P, Pollard, A

“…BACKGROUND: In a previous study, 60 infants receiving an investigational serogroup B meningococcal vaccine containing recombinant meningococcal proteins alone (rMenB) or combined with an outer membrane vesicle from Neisseria meningitidis (4CMenB) at 6, 8 and 12 months of age produced serum bactericidal antibodies (SBAs) against meningococcal strains expressing vaccine antigens. …”

Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster... by Snape, MD, Philip, J, John, T, Robinson, H, Kelly, S, Gossger, N, Yu, L, Kittel, C, Toneatto, D, Dull, P, Pollard, A

“…Background: In a previous study, 60 infants receiving an investigational serogroup B meningococcal vaccine containing recombinant meningococcal proteins alone (rMenB) or combined with an outer membrane vesicle from Neisseria meningitidis (4CMenB) at 6, 8 and 12 months of age produced serum bactericidal antibodies (SBAs) against meningococcal strains expressing vaccine antigens. …”

Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial. by Khatami, A, Snape, MD, John, T, Westcar, S, Klinger, C, Rollinson, L, Boutriau, D, Mesaros, N, Wysocki, J, Galaj, A, Yu, L, Pollard, A

“… BACKGROUND: Antibodies against Haemophilus influenzae type b (Hib) and serogroup C Neisseria meningitidis (MenC) wane after early infant immunization. …”

A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial by Pace, D, Snape, M, Westcar, S, Oluwalana, C, Yu, L, Begg, N, Wysocki, J, Czajka, H, Maechler, G, Boutriau, D, Pollard, A

“…Objective: To study the immunogenicity and reactogenicity of a combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine (Hib-MenC-TT) when administered as a booster dose in combination with a measles, mumps and rubella vaccine (MMR). …”

A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial. by Pace, D, Snape, M, Westcar, S, Oluwalana, C, Yu, L, Begg, N, Wysocki, J, Czajka, H, Maechler, G, Boutriau, D, Pollard, A

“… OBJECTIVE: To study the immunogenicity and reactogenicity of a combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine (Hib-MenC-TT) when administered as a booster dose in combination with a measles, mumps and rubella vaccine (MMR). …”

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedu... by Gossger, N, Snape, MD, Yu, L, Finn, A, Bona, G, Esposito, S, Principi, N, Diez-Domingo, J, Sokal, E, Becker, B, Kieninger, D, Prymula, R, Dull, P, Ypma, E, Toneatto, D, Kimura, A, Pollard, A

“…CONTEXT: In the absence of an effective vaccine, serogroup B Neisseria meningitidis (MenB) remains a major cause of invasive disease in early childhood in developed countries. …”

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. by Snape, MD, Perrett, K, Ford, K, John, T, Pace, D, Yu, L, Langley, J, McNeil, S, Dull, P, Ceddia, F, Anemona, A, Halperin, SA, Dobson, S, Pollard, A

“…INTERVENTION: UK infants received a primary course of MenACWY (at 2, 3, and 4 months or 2 and 4 months) or Neisseria meningitidis serogroup C monovalent meningococcal glycoconjugate vaccine (MenC) (at 2 and 4 months). …”

Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study. by Khatami, A, Snape, MD, Wysocki, J, John, T, Westcar, S, Mesaros, N, Peddiraju, K, Boutriau, D, Yu, L, Pollard, A

“… BACKGROUND: Antibodies against Haemophilus influenzae type b (Hib) and serogroup C Neisseria meningitidis (MenC) persist better to 3½ years of age after a 12-month booster dose of a combination Hib-MenC glycoconjugate vaccine (Hib-MenC-TT) in children primed in infancy with Hib-MenC-TT and diphtheria-tetanus-acellular-pertussis-inactivated poliovirus vaccine (DTaP-IPV) than in those who received a monovalent MenC-CRM197 and DTaP-IPV-Hib (also TT conjugated). …”

CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. by Kelly, D, Snape, MD, Clutterbuck, E, Cutterbuck, E, Green, S, Snowden, C, Diggle, L, Yu, L, Borkowski, A, Moxon, E, Pollard, A

“…Neisseria meningitidis is one of the leading causes of bacterial meningitis and septicemia in children. …”